Amplia Receives R&D Tax Rebate Totalling $3.2 Million
Filed with ASX · · 1 page · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Granting of Key Patent in Europe and Japan
- Additional Patient Response in Pancreatic Cancer Trial
- Sustained Reduction in Tumour Size Seen In Pancreatic Trial
- First 26 Patients recruited in Phase 2A ACCENT Trial
- Preliminary Final Report and Annual Report YE 31 March 2024
Later from Amplia Therapeutics
- Fifth Confirmed Response in ACCENT Trial
- FDA Fast Track Designation for Narmafotinib
- Sixth Confirmed Response in Pancreatic Cancer Trial
- Interim Data From Accent Pancreatic Cancer Trial
- Amplia to Raise up to $13m for ACCENT and US Trials
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics